Abstract
Translation of genomic discoveries into patient care is slowly becoming a reality in developed economies around the world. In contrast, low- and middle-income countries (LMIC) have participated minimally in genomic research for several reasons including the lack of coherent national policies, the limited number of well-trained genomic scientists, poor research infrastructure, and local economic and cultural challenges. Recent initiatives such as the Human Heredity and Health in Africa (H3Africa), the Qatar Genome Project, and the Mexico National Institute of Genomic Medicine (INMEGEN) that aim to address these problems through capacity building and empowerment of local researchers have sparked a paradigm shift. In this short communication, we describe experiences of small-scale medical genetics and translational genomic research programs in LMIC. The lessons drawn from these programs drive home the importance of addressing resource, policy, and sociocultural dynamics to realize the promise of precision medicine driven by genomic science globally. By echoing lessons from a bench-to-community translational genomic research, we advocate that large-scale genomic research projects can be successfully linked with health care programs. To harness the benefits of genomics-led health care, LMIC governments should begin to develop national genomics policies that will address human and technology capacity development within the context of their national economic and sociocultural uniqueness. These policies should encourage international collaboration and promote the link between the public health program and genomics researchers. Finally, we highlight the potential catalytic roles of the global community to foster translational genomics in LMIC.
References
1.
Manolio TA, Chisholm RL, Ozenberger B, Roden DM, Williams MS, Wilson R, Bick D, Bottinger EP, Brilliant MH, Eng C, et al: Implementing genomic medicine in the clinic: the future is here. Genet Med 2013;15:258-267.
2.
H3Africa Consortium; Rotimi C, Abayomi A, Abimiku A, et al: Research capacity. Enabling the genomic revolution in Africa. Science 2014;344:1346-1348.
3.
Gurdasani D, Carstensen T, Tekola-Ayele F, Pagani L, Tachmazidou I, Hatzikotoulas K, Karthikeyan S, Iles L, Pollard MO, Choudhury A, et al: The African Genome Variation Project shapes medical genetics in Africa. Nature 2015;517:327-332.
4.
Moreno-Estrada A, Gignoux CR, Fernandez-Lopez JC, Zakharia F, Sikora M, Contreras AV, Acuna-Alonzo V, Sandoval K, Eng C, Romero-Hidalgo S, et al: Human genetics. The genetics of Mexico recapitulates Native American substructure and affects biomedical traits. Science 2014;344:1280-1285.
5.
McKinnell JA, Saag MS: Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists]. Curr Opin HIV AIDS 2009;4:513-517.
6.
Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, et al: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727-732.
7.
Department of Health of the Republic of South Africa: The South African Antiretroviral Treatment Guidelines 2013. Pretoria, Department of Health, 2013.
8.
Federal Ministry of Health: Guidelines for Management of Opportunistic Infections and Antiretroviral Treatment in Adolescents and Adults in Ethiopia. Addis Ababa, Federal Ministry of Health, 2008.
9.
Rotimi CN, Jorde LB: Ancestry and disease in the age of genomic medicine. N Engl J Med 2010;363:1551-1558.
10.
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, et al: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
11.
Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, et al: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
12.
Kamal SM: Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. Hepat Med 2014;6:61-77.
13.
Graham CS, Swan T: A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Res 2015;119:89-96.
14.
Drogemoller BI, Wright GE, Niehaus DJ, Emsley RA, Warnich L: Whole-genome resequencing in pharmacogenomics: moving away from past disparities to globally representative applications. Pharmacogenomics 2011;12:1717-1728.
15.
Aklillu E, Djordjevic N, Carrillo JA, Makonnen E, Bertilsson L, Ingelman-Sundberg M: High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. OMICS 2014;18:446-453.
16.
Tekola-Ayele F, Adeyemo A, Aseffa A, Hailu E, Finan C, Davey G, Rotimi CN, Newport MJ: Clinical and pharmacogenomic implications of genetic variation in a Southern Ethiopian population. Pharmacogenomics J 2015;15:101-108.
17.
Ramos E, Doumatey A, Elkahloun AG, Shriner D, Huang H, Chen G, Zhou J, McLeod H, Adeyemo A, Rotimi CN: Pharmacogenomics, ancestry and clinical decision making for global populations. Pharmacogenomics J 2014;14:217-222.
18.
Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053.
19.
Sun Q, van Dam RM, Willett WC, Hu FB: Prospective study of zinc intake and risk of type 2 diabetes in women. Diabetes Care 2009;32:629-634.
20.
Travers ME, McCarthy MI: Type 2 diabetes and obesity: genomics and the clinic. Hum Genet 2011;130:41-58.
21.
Romieu I, Sienra-Monge JJ, Ramirez-Aguilar M, Moreno-Macias H, Reyes-Ruiz NI, Estela del Rio-Navarro B, Hernandez-Avila M, London SJ: Genetic polymorphism of GSTM1 and antioxidant supplementation influence lung function in relation to ozone exposure in asthmatic children in Mexico City. Thorax 2004;59:8-10.
22.
Romieu I, Ramirez-Aguilar M, Sienra-Monge JJ, Moreno-Macias H, del Rio-Navarro BE, David G, Marzec J, Hernandez-Avila M, London S: GSTM1 and GSTP1 and respiratory health in asthmatic children exposed to ozone. Eur Respir J 2006;28:953-959.
23.
Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, et al: Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010;329:841-845.
24.
Behar DM, Kedem E, Rosset S, Haileselassie Y, Tzur S, Kra-Oz Z, Wasser WG, Shenhar Y, Shahar E, Hassoun G, et al: Absence of APOL1 risk variants protects against HIV-associated nephropathy in the Ethiopian population. Am J Nephrol 2011;34:452-459.
25.
Tayo BO, Kramer H, Salako BL, Gottesman O, McKenzie CA, Ogunniyi A, Bottinger EP, Cooper RS: Genetic variation in APOL1 and MYH9 genes is associated with chronic kidney disease among Nigerians. Int Urol Nephrol 2013;45:485-494.
26.
Ulasi II, Tzur S, Wasser WG, Shemer R, Kruzel E, Feigin E, Ijoma CK, Onodugo OD, Okoye JU, Arodiwe EB, et al: High population frequencies of APOL1 risk variants are associated with increased prevalence of non-diabetic chronic kidney disease in the Igbo people from south-eastern Nigeria. Nephron Clin Pract 2013;123:123-128.
27.
Kofman T, Audard V, Narjoz C, Gribouval O, Matignon M, Leibler C, Desvaux D, Lang P, Grimbert P: APOL1 polymorphisms and development of CKD in an identical twin donor and recipient pair. Am J Kidney Dis 2014;63:816-819.
28.
World Health Organization: Community Genetics Services: Report of a WHO Consultation on Community Genetics in Low- and Middle-Income Countries. Geneva, WHO, 2010.
29.
al-Hosani H, Salah M, Saade D, Osman H, al-Zahid J: United Arab Emirates National Newborn Screening Programme: an evaluation 1998-2000. East Mediterr Health J 2003;9:324-332.
30.
Greenberg J, Roberts L, Bruwer Z, Schoeman M, Loggenberg K, Loubser F: Delivery of an ophthalmic genetic service in South Africa. S Afr Ophthalmol J 2010;5:14-19.
31.
Wonkam A, Tekendo CN, Sama DJ, Zambo H, Dahoun S, Bena F, Morris MA: Initiation of a medical genetics service in sub-Saharan Africa: experience of prenatal diagnosis in Cameroon. Eur J Med Genet 2011;54:e399-e404.
32.
Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, Temperley WH, Williams TN, Weatherall DJ, Hay SI: Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2013;381:142-151.
33.
Grosse SD, Atrash HK, Odame I, Amendah D, Piel FB, Williams TN: The Jamaican historical experience of the impact of educational interventions on sickle cell disease child mortality. Am J Prev Med 2012;42:e101-e103.
34.
Makani J, Soka D, Rwezaula S, Krag M, Mghamba J, Ramaiya K, Cox SE, Grosse SD: Health policy for sickle cell disease in Africa: experience from Tanzania on interventions to reduce under-five mortality. Trop Med Int Health 2015;20:184-187.
35.
Galadanci N, Wudil BJ, Balogun TM, Ogunrinde GO, Akinsulie A, Hasan-Hanga F, Mohammed AS, Kehinde MO, Olaniyi JA, Diaku-Akinwumi IN, et al: Current sickle cell disease management practices in Nigeria. Int Health 2014;6:23-28.
36.
Tshilolo L, Aissi LM, Lukusa D, Kinsiama C, Wembonyama S, Gulbis B, Vertongen F: Neonatal screening for sickle cell anaemia in the Democratic Republic of the Congo: experience from a pioneer project on 31 204 newborns. J Clin Pathol 2009;62:35-38.
37.
Ohene-Frempong K, Oduro J, Tetteh H, Nkrumah F: Screening newborns for sickle cell disease in Ghana. Pediatrics 2008;121:S120.
38.
Knoppers BM, Senecal K, Borry P, Avard D: Whole-genome sequencing in newborn screening programs. Sci Transl Med 2014;6:229cm222.
39.
Yoon PW, Scheuner MT, Peterson-Oehlke KL, Gwinn M, Faucett A, Khoury MJ: Can family history be used as a tool for public health and preventive medicine? Genet Med 2002;4:304-310.
40.
Williams RR, Hunt SC, Heiss G, Province MA, Bensen JT, Higgins M, Chamberlain RM, Ware J, Hopkins PN: Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). Am J Cardiol 2001;87:129-135.
41.
Hulse NC, Ranade-Kharkar P, Post H, Wood GM, Williams MS, Haug PJ: Development and early usage patterns of a consumer-facing family health history tool. AMIA Annu Symp Proc 2011;2011:578-587.
42.
Orlando LA, Hauser ER, Christianson C, Powell KP, Buchanan AH, Chesnut B, Agbaje AB, Henrich VC, Ginsburg G: Protocol for implementation of family health history collection and decision support into primary care using a computerized family health history system. BMC Health Serv Res 2011;11:264.
43.
Davey G, Gebrehanna E, Adeyemo A, Rotimi C, Newport M, Desta K: Podoconiosis: a tropical model for gene-environment interactions? Trans R Soc Trop Med Hyg 2007;101:91-96.
44.
Tekola Ayele F, Adeyemo A, Finan C, Hailu E, Sinnott P, Burlinson ND, Aseffa A, Rotimi CN, Newport MJ, Davey G: HLA class II locus and susceptibility to podoconiosis. N Engl J Med 2012;366:1200-1208.
45.
Tekola Ayele F, Adeyemo A, Rotimi CN: Using a ‘genomics tool' to develop disease prevention strategy in a low-income setting: lessons from the podoconiosis research project. J Community Genet 2012;3:303-309.
46.
Ayode D, McBride CM, de Heer H, Watanabe E, Gebreyesus T, Tadele G, Tora A, Davey G: The association of beliefs about heredity with preventive and interpersonal behaviors in communities affected by podoconiosis in rural Ethiopia. Am J Trop Med Hyg 2012;87:623-630.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
